Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss ...

Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.

Johnson & Johnson is building up its immunology pipeline, striking a $1.25 billion deal for a bispecific antibody in development for atopic dermatitis — its second acquisition agreement in the ...

Atopic dermatitis (AD) is a type of eczema, a condition that makes skin dry, red, and itchy. There are many ways to tame its symptoms, from creams that control itching to light therapy. But about half ...

Exposure to dupilumab is associated with an increased risk of being diagnosed with cutaneous autoimmune diseases in children ...

Treatment with abrocitinib, an oral JAK1 inhibitor, led to substantial improvements in the signs and symptoms of chronic hand ...